Question explored with the scientific record
Is celcept a safe drug for RA-ILD?
The evidence for CellCept (mycophenolate mofetil) in RA-ILD is almost entirely borrowed from a different disease, systemic sclerosis (SSc-ILD), and no trial has tested it head-to-head against a placebo or an untreated group in rheumatoid arthritis patients.
The best evidence comes from the Scleroderma Lung Study II (SLS II), a randomized trial of 142 SSc-ILD patients that compared mycophenolate to cyclophosphamide [1]. It found no significant difference in the primary endpoint of FVC change at 24 months, though mycophenolate had a better safety profile with fewer withdrawals [1, 2]. A 2012 meta-analysis of six small SSc-ILD studies found no statistically significant improvement in lung function, only a suggestion of a favorable safety profile [3]. The 2024 narrative review calls mycophenolate "first-line" for SSc-ILD, but that is a consensus opinion, not a proven verdict from a placebo-controlled trial [2].
For RA-ILD specifically, the retrieved evidence is silent. One 2025 study of 569 RA patients found that those with ILD had higher long-term disease activity and infection risk, but it did not test any drug [8]. A 2025 review on COVID-19 in rheumatic disease warns that mycophenolate mofetil markedly increases hospitalization and death risk from infection [4]. That is a real safety signal.
The known harms of mycophenolate are documented in other contexts: gastrointestinal intolerance, leukopenia, infections, and rare but serious effects like drug-induced depression and oral ulcers [5, 6, 7]. The drug is a potent immunosuppressant that broadly suppresses lymphocyte proliferation. In a lung already damaged by inflammation, suppressing the immune system carries the risk of worsening infections without proven benefit.
| Comparison | What the evidence shows |
|---|---|
| Mycophenolate vs placebo in RA-ILD | No trial exists |
| Mycophenolate vs cyclophosphamide in SSc-ILD | No difference in FVC; fewer side effects [1] |
| Mycophenolate in SSc-ILD (meta-analysis) | No significant lung function improvement [3] |
| Infection risk with mycophenolate in RA | Markedly increased [4] |
My call: the evidence does not support CellCept as a safe or proven drug for RA-ILD. The benefit is unproven in this population, and the infection risk is real and documented. Confidence: low.
Sources used 8
-
Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era
Evidence synthesis indicates immunosuppressants (especially mycophenolate over cyclophosphamide) show how SSc-ILD can be managed in the modern era, with autoHCT and emerging antifibrotic/biologic therapies offering additional options, though optimal timing and maintenance remain…
DOI: 10.5301/jsrd.5000237 -
A Narrative Review of Therapeutic Options in Systemic Sclerosis Associated Interstitial Lung Disease
This narrative review synthesizes landmark randomized trials and guidelines on systemic sclerosis–associated interstitial lung disease (SSc-ILD), concluding mycophenolate mofetil (MMF) as the recommended first-line therapy with rituximab, cyclophosphamide, or tocilizumab as opti…
DOI: 10.3390/sclerosis2040018 -
Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
This meta-analysis evaluates the safety and efficacy of Mycophenolate Mofetil (MMF) and Mycophenolate Sodium (MMS) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), finding no statistically significant improvement in lung function but suggesting…
DOI: 10.1155/2012/143637 -
COVID-19 in Autoimmune Rheumatic Diseases: Lessons Learned and Emerging Risk Stratification Approaches
In autoimmune and autoinflammatory rheumatic diseases, COVID-19 is usually mild, but older age, interstitial lung disease, and therapies such as rituximab, mycophenolate mofetil, or high-dose corticosteroids markedly increase hospitalization and death risk, while cytokine-target…
DOI: 10.29245/2578-3009/2025/4.1262 -
Oral ulcers associated with mycophenolate mofetil use in a renal transplant recipient
This case study reports a 23-year-old renal transplant recipient who developed oral ulcers as a rare adverse effect of mycophenolate mofetil therapy, which resolved rapidly after discontinuation of the drug.
DOI: 10.2146/ajhp100276 -
Depressive Disorder Associated with Mycophenolate Mofetil
This case report documents a probable drug-induced depressive disorder temporally associated with mycophenolate mofetil (MMF) in a 64-year-old woman with myasthenia gravis, showing symptom onset after MMF initiation, resolution after discontinuation, and recurrence upon rechalle…
DOI: 10.1592/phco.28.1.136 -
Renal Transplant Patients With Gastrointestinal Intolerability to Mycophenolate Mofetil: Conversion to Enteric-Coated Mycophenolate Sodium
This study demonstrates that converting renal transplant patients from mycophenolate mofetil to enteric-coated mycophenolate sodium significantly reduces gastrointestinal adverse events while improving serum creatinine levels and mycophenolic acid absorption.
DOI: 10.1016/j.transproceed.2006.08.085 -
Differential impacts of interstitial lung disease and airway disease on rheumatoid arthritis disease activity and infection
A retrospective Kanazawa University hospital cohort study disentangles the independent effects of interstitial lung disease (ILD) and airway disease (AD) on rheumatoid arthritis (RA) activity and infection risk, finding ILD linked to higher long-term RA activity and later infect…
DOI: 10.1038/s41598-025-23080-1